Alterome Therapeutics is focused on developing next-generation, small molecule targeted therapies for precision treatment of cancer. Their approach is centered around identifying and targeting specific alterations within cancer cells, leading to the development of highly selective and potent therapeutic agents. Alterome's pipeline leverages their in-house platform, The Kraken, which uses computational chemistry to design targeted cancer therapies. One of Alterome's key areas of research is the development of inhibitors for KRAS mutations. They developed ALTA-2618, an orally bioavailable, mutant-selective, and covalent allosteric inhibitor of AKT1 E17K. They are also exploring other high-value and validated oncogenic targets.

Alterome Therapeutics

Founded: 2021
Location: San Diego, California
Employee range: 1-50
Clinical stage: Clin0
Therapy area: Oncology
Drug types: ONC
Lead product: ALTA-2618
Funding: 100 - 500M

Drug notes:

About:

Jobs: